 Connection
Larry Moreland to Animals
This is a "connection" page, showing publications Larry Moreland has written about Animals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.203 |
|
|
|
-
Moreland LW, Kuhn K. Editorial overview: Special issue on "Rheumatology: Therapeutic advances for autoimmune and musculoskeletal diseases". Curr Opin Pharmacol. 2024 06; 76:102462.
Score: 0.043
-
Mackey RH, Kuller LH, Moreland LW. Inflammatory joint diseases and atherosclerosis: time to look beyond the 'lipid paradox'. Curr Opin Lipidol. 2019 08; 30(4):342-349.
Score: 0.031
-
Moreland LW. Cytokines as targets for anti-inflammatory agents. Ann N Y Acad Sci. 2009 Dec; 1182:88-96.
Score: 0.016
-
Bhamidipati K, McIntyre ABR, Kazerounian S, Ce G, Wong SW, Tran M, Prell SA, Lau R, Khedgikar V, Altmann C, Small A, Madhu R, Presti SR, Anufrieva KS, Blazar PE, Lange JK, Seifert JA, Moreland LW, Croft AP, Smith MH, Donlin LT, Lewis MJ, Jonsson AH, Pitzalis C, Thomas R, Gravallese EM, Brenner MB, Korsunsky I, Wechalekar MD, Wei K. Spatial patterning of fibroblast TGFß signaling underlies treatment resistance in rheumatoid arthritis. Nat Immunol. 2026 Mar; 27(3):556-571.
Score: 0.012
-
Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005 Sep; 5(9):1245-54.
Score: 0.012
-
Robinson WH, Fiorentino D, Chung L, Moreland LW, Deodhar M, Harler MB, Saulsbery C, Kunder R. Cutting-edge approaches to B-cell depletion in autoimmune diseases. Front Immunol. 2024; 15:1454747.
Score: 0.011
-
Abbott JD, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2004 Aug; 13(8):1007-18.
Score: 0.011
-
Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
Score: 0.009
-
Moreland LW. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. Isr Med Assoc J. 2001 Sep; 3(9):686-90.
Score: 0.009
-
Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001 Jan; 2(1):75-84.
Score: 0.009
-
Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
Score: 0.008
-
Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med. 1998 Feb 01; 128(3):231-3.
Score: 0.007
-
Moreland LW, Bucy RP, Koopman WJ. Regeneration of T cells after chemotherapy. N Engl J Med. 1995 Jun 15; 332(24):1651-2.
Score: 0.006
-
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014 Feb 20; 506(7488):376-81.
Score: 0.005
-
Moreland LW, Koopman WJ. Infection as a cause of reactive arthritis, ankylosing spondylitis, and rheumatic fever. Curr Opin Rheumatol. 1992 Aug; 4(4):534-42.
Score: 0.005
-
Moreland LW, Koopman WJ. Infection as a cause of arthritis. Curr Opin Rheumatol. 1991 Aug; 3(4):639-49.
Score: 0.004
-
Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008 Jun; 58(6):1810-22.
Score: 0.004
-
Jeffcoat MK, Reddy MS, Moreland LW, Koopman WJ. Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. Ann N Y Acad Sci. 1993 Nov 30; 696:292-302.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|